The global long read sequencing market revenue was around US$ 738 million in 2022 and is estimated to reach US$ 4,517 million by 2031, growing at a compound annual growth rate (CAGR) of 22.3% during the forecast period from 2023 to 2031.
Long-read sequencing is a Deoxyribonucleic acid (DNA) sequencing technique presently being researched which can determine the nucleotide sequence of long sequences of DNA between 10,000 and 100,000 base pairs at a time. This releases the requirement to cut up and then amplify DNA which is normally needed in other DNA sequencing techniques.
Market Driving Factors
An increase in incidences of genetic disorders is projected to boost the market growth. For instance, according to the Centers for Disease Control and Prevention, sickle cell disease affects about 100,000 individuals in the United States. In addition, the progress in the patients would attract the attention of common of the key companies to bring up keys.
The surge in leading manufacturer's R&D investments in long-read sequencing technologies, integrated with a growth in the prevalence of genetic disorders, is likely to create opportunities in the market. This is primarily due to the long-read technique that is mainly employed to investigate genetic disorders for which disorders are either extremely suspected or known. Furthermore, long-read sequencing procedures have the potential to alleviate some of the drawbacks of next-generation sequencing-based clinical illness research. As a result, long-read sequencing technologies have a substantial benefit over their competitors since they utilize longer reads that come from a single DNA molecule.
Lack of experienced professionals and legal and ethical limitations are estimated to hamper the market growth.
Regional Analysis
North America dominated the market in terms of the largest shares and is estimated to continue its dominance. This can be majorly attributed to various factors such as the availability of a strong informatics network, well-established rules for approval and distribution of genomic testing services & products, and the existence of key players such as Pacific Biosciences in the region. Furthermore, the surge in the adoption of genomic procedures for different academic and clinical usage in the United States is anticipated to drive market growth in the region.
Asia Pacific is estimated to dominate the market in terms of the growth rate. This is primarily owing to the surging penetration of key players in emerging markets in the region, and the increase in investments for the development of cutting-edge diagnostic methods.
Segmentation Insights
Application Insight
The research application segment dominated the market in terms of the growth rate and is estimated to continue its dominance. This can be majorly attributed to the surge in investments by key players toward R&D related to long-read sequencing applications.
Clinical application is estimated to dominate the market in terms of the fastest growth. This is primarily owing to the rise in the prevalence of genetic disorders and chronic illnesses such as cancer.
Product Insight
The consumable segment is predicted to dominate the market in terms of revenue. This is primarily due to the advent of novel pre-sequencing kits and products for executing DNA fragmentation, size selection, target enrichment, and others.
End User Insight
The pharmaceutical & biotechnological companies segment is predicted to dominate the market in terms of the shares. This is primarily due to the surge in financing of pharmaceutical and biotech companies in sequence analysis research to understand the complicated pattern of drug resistance developed by oncology, microorganisms, drug discovery, and molecular aspects of cancer.
Academic and government research institutes segment dominate the market in terms of revenue. This is primarily owing to the existence of a large number of research institutes that explore genome sequencing methodologies and molecular biology. Additionally, increasing usage of sequence analysis methodologies in academic workshops, research, and on-site bioinformatics courses provided by universities is anticipated to propel the academic and government research institutes segment.
Prominent Companies
Segmentation Outline
The global long read sequencing market segmentation focuses on the Application, Techniques, Product, End User, and Region.
By Application
By Techniques
By Product
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL LONG READ SEQUENCING MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: LONG READ SEQUENCING MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL LONG READ SEQUENCING MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL LONG READ SEQUENCING MARKET, BY APPLICATION
5.1 OVERVIEW
5.2 RESEARCH APPLICATIONS
5.3 CLINICAL APPLICATIONS
6 GLOBAL LONG READ SEQUENCING MARKET, BY TECHNIQUES
6.1 OVERVIEW
6.2 SINGLE-MOLECULE REAL-TIME SEQUENCING
6.3 NANOPORE SEQUENCING
6.4 OTHERS
7 GLOBAL LONG READ SEQUENCING MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 SYSTEM
7.2.2 SOFTWARE
7.3 CONSUMABLES
7.4 SERVICES
8 GLOBAL LONG READ SEQUENCING MARKET, BY END USER
8.1 OVERVIEW
8.2 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
8.3 PHARMACEUTICAL AND BIOTECH COMPANIES
8.4 HOSPITALS AND CLINICS
8.5 OTHERS
9 GLOBAL LONG READ SEQUENCING MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3.1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL LONG READ SEQUENCING MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
10.4 COMPETITIVE DASHBOARD
10.5 PRODUCT MAPPING
10.6 TOP PLAYER POSITIONING, 2022
10.7 COMPETITIVE HEATMAP
10.8 TOP WINNING STRATEGIES
11 COMPANY PROFILES
11.1 CANTATA BIO
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.2 AGILENT TECHNOLOGIES
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.3 PACIFIC BIOSCIENCES OF CALIFORNIA INC
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.4 MICROBESNG
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.5 GRANDOMICS
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.6 FUTURE GENOMICS TECHNOLOGIES B.V
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.7 F. HOFFMANN-LA ROCHE LTD
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.8 OXFORD NANOPORE TECHNOLOGIES LIMITED
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.9 ILLUMINA INC
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.10 ELEMENT BIOSCIENCE
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.11 GENOME TRANSCRIPTOME FACILITY OF BORDEAUX
11.11.1 OVERVIEW
11.11.2 FINANCIAL PERFORMANCE
11.11.3 PRODUCT OUTLOOK
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.12 THERMO FISHER SCIENTIFIC INC.
11.12.1 OVERVIEW
11.12.2 FINANCIAL PERFORMANCE
11.12.3 PRODUCT OUTLOOK
11.12.4 KEY DEVELOPMENTS
11.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.13 ST VINCENTS HOSPITAL AUSTRALIA
11.13.1 OVERVIEW
11.13.2 FINANCIAL PERFORMANCE
11.13.3 PRODUCT OUTLOOK
11.13.4 KEY DEVELOPMENTS
11.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.14 BASECLEAR B.V.
11.14.1 OVERVIEW
11.14.2 FINANCIAL PERFORMANCE
11.14.3 PRODUCT OUTLOOK
11.14.4 KEY DEVELOPMENTS
11.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.15 NOVOGENE
11.15.1 OVERVIEW
11.15.2 FINANCIAL PERFORMANCE
11.15.3 PRODUCT OUTLOOK
11.15.4 KEY DEVELOPMENTS
11.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.16 TAKARA BIO INC
11.16.1 OVERVIEW
11.16.2 FINANCIAL PERFORMANCE
11.16.3 PRODUCT OUTLOOK
11.16.4 KEY DEVELOPMENTS
11.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.17 JIANGSU HENGRUI PHARMACEUTICALS CO. LTD
11.17.1 OVERVIEW
11.17.2 FINANCIAL PERFORMANCE
11.17.3 PRODUCT OUTLOOK
11.17.4 KEY DEVELOPMENTS
11.17.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved